Effect of raloxifene on vascular endothelial growth factor expression in breast carcinomas of postmenopausal women

Cell Proliferation

Volumn 42, Issue 4, 2009, Pages 506-510

  Da Silva, B B ^a,b   Dos Santos, A R ^a   Pires, C G ^a   Lopes Costa, P V ^a  

^a FEDERAL UNIVERSITY OF PIAUÍ   (Brazil)

^b Jockey Club de Sao Paulo   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR; RALOXIFENE; VASCULOTROPIN;

ADULT; AGED; ANTIANGIOGENIC ACTIVITY; ANTIANGIOGENIC THERAPY; ARTICLE; BREAST CANCER; BREAST CARCINOMA; CANCER INHIBITION; CLINICAL ARTICLE; CLINICAL TRIAL; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; POSTMENOPAUSE; PREOPERATIVE TREATMENT; PROTEIN EXPRESSION;

AGED; CARCINOMA, DUCTAL, BREAST; ESTROGEN ANTAGONISTS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; POSTMENOPAUSE; RALOXIFENE; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 67649881466     PISSN: 09607722     EISSN: 13652184     Source Type: Journal    
DOI: 10.1111/j.1365-2184.2009.00615.x     Document Type: Article

References (37)

1. Folkman J (1971) Tumor angiogenesis: therapeutic implications. N. Engl. J Med. 285, 1182-1186.
2. Garvin S, Dabrosin C (2003) Tamoxifen inhibits secretion of vascular endothelial growth factor in breast cancer in vivo. Cancer Res. 63, 8742-8748.
3. Ferrara N (2004) Vascular endothelial growth factor as a target for anticancer therapy. Oncologist 9, 2-10.
4. da Silva BB, Lopes IM, Gebrim LH (2006) Effects of raloxifene on normal breast tissue from premenopausal women. Breast Cancer Res. Treat. 95, 99-103.
5. Ferrara N (2001) Role of vascular endothelial growth factor in regulation of physiological angiogenesis. Am. J Physiol. Cell Physiol. 280, 1358-1366.
6. Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z (1999) Vascular endothelial growth factor (VEGF) and its receptors. FASEB J. 13, 9-22.
7. Alon T, Hemo I, Itin A, Pe'er J, Stone J, Keshet E (1995) Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity. Nat. Med. 1, 1024-1028.
8. Ferrara N (2002) Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications. Semin. Oncol. 29, 10-14.
9. Dabrosin C (2005) Positive correlation between estradiol and vascular endothelial growth factor but not fibroblast growth factor-2 in normal human breast tissue in vivo. Clin. Cancer Res. 11, 8036-8041.
10. Garvin S, Dabrosin C (2008) In vivo measurement of tumor estradiol and vascular endothelial growth factor in breast cancer patients. BMC Cancer 8, 73.
11. Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, Vogel V, Robidoux A, Dimitrov N, Atkins J, Daly M, Wieand S, Tan-Chiu E, Ford L, Wolmark N (1998) Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-I Study. J Natl. Cancer Inst. 90, 1371-1388.
12. Ruohola JK, Valve EM, Karkkainen MJ, Joukov V, Alitalo K, Härkönen PL ( 1999) Vascular endothelial growth factors are differentially regulated by steroid hormones and antiestrogens in breast cancer cells. Mol. Cell. Endocrinol. 149, 29-40.
13. Swerdlow AJ, Jones ME, British Tamoxifen Second Cancer Study Group (2005) Tamoxifen treatment for breast cancer and risk of endometrial cancer: a case-control study. J Natl. Cancer Inst. 91, 375-384.
14. Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, Christiansen C, Delmas PD, Zanchetta JR, Stakkestad J, Glüer CC, Krueger K, Cohen FJ, Eckert S, Ensrud KE, Avioli LV, Lips P, Cummings SR (1999) Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 282, 637-645.
15. Cummings SR, Eckert S, Krueger KA, Grady D, Powles TJ, Cauley JA, Norton L, Nickelsen T, Bjarnason NH, Morrow M, Lippman ME, Black D, Glusman JE, Costa A, Jordan VC (1999) The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA 281, 2189-2197.
16. Vogel VG, Costantino JP, Wickerham DL, Cronin WM, Cecchini RS, Atkins JN, Bevers TB, Fehrenbacher L, Pajon ER Jr, Wade JL 3rd, Robidoux A, Margolese RG, James J, Lippman SM, Runowicz CD, Ganz PA, Reis SE, McCaskill-Stevens W, Ford LG, Jordan VC, Wolmark N; National Surgical Adjuvant Breast and Bowel Project (NSABP) (2006) Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 295,2727-2741.
17. Jolly EE, Bjarnason NH, Neven P, Plouffe L Jr, Johnston CC Jr, Watts SD, Arnaud CD, Mason TM, Crans G, Akers R, Draper MW (2003) Prevention of osteoporosis and uterine effects in postmenopausal women taking raloxifene for 5 years. Menopause 10, 337-344.
18. Dowsett M, Bundred NJ, Decensi A, Sainsbury RC, Lu Y, Hills MJ, Cohen FJ, Veronesi P, O'Brien ME, Scott T, Muchmore DB (2001) Effect of raloxifene on breast cancer cell Ki67 and apoptosis: a double-blind, placebo-controlled, randomized clinical trial in postmenopausal patients. Cancer Epidemiol. Biomarkers Prev. 10, 961-966.
19. da Silva BB, de Carvalho Gonçalves Nunes Galvão ER, Dos Santos LG (2006b) Evaluation of CD34 antigen expression following tamoxifen as primary treatment for breast cancer. Int. J. Gynaecol. Obstet. 93, 70-71.
20. Mirkin S, Wong BC, Archer DF (2006) Effects of 17β-estradiol, progesterone, synthetic progestins, tibolone, and raloxifene on vascular endothelial growth factor and thrombospondin-1 messenger RNA in breast cancer cells. Int. J Gynecol. Cancer 16, 560-563.
21. Thike AA, Chng MJ, Fook-Chong S, Tan PH (2001) Immunohistochemical expression of hormone receptors in invasive breast carcinoma: correlation of results of H-score with pathological parameters. Pathology 33, 21-25.
22. van Slooten HJ, Clahsen PC, van Dierendonck JH, Duval C, Pallud C, Mandard AM, Delobelle-Deroide A, van de Velde CJ, van de Vijver MJ (1996) Expression of Bcl-2 in node-negative breast cancer is associated with various prognostic factors, but does not predict response to one course of perioperative chemotherapy. Br. J. Cancer 74, 78-85.
23. Agresti A (2002) Categorical Data Analysis, 2nd edn. New York: John Wiley & Sons.
24. Jacobs TW, Siziopikou KP, Prioleau JE, Raza S, Baum JK, Hayes DF, Schnitt SJ (1998) Do prognostic marker studies on core needle biopsy specimens of breast carcinoma accurately reflect the marker status of the tumor? Mod. Pathol. 11, 259-264.
25. Marson LP, Kurian KM, Miller WR, Dixon JM (1999) Reproducibility of microvessel counts in breast cancer specimens. Br. J Cancer 81, 1088-1093.
26. Marson LP, Kurian KM, Miller WR, Dixon JM (2001) The effect of tamoxifen on breast tumour vascularity. Breast Cancer Res. Treat. 66, 9-15.
27. Jordan VC, O'Malley BW (2007) Selective estrogen-receptor modulators and antihormonal resistance in breast cancer. J Clin. Oncol. 25, 5815-5824.
28. Lewis JS, Jordan VC (2005) Selective estrogen receptor modulators (SERMs): mechanisms of anticarcinogenesis and drug resistance. Mutat. Res. 591, 247-263.
29. Hall JM, McDonnell DP (1999) The estrogen receptor β-isoform (ERβ) of the human estrogen receptor modulates ERα transcriptional activity and is a key regulator of the cellular response to estrogens and antiestrogens. Endocrinology 140, 5566-5578.
30. da Silva BB, da Silva Júnior RG, Borges US, da Silveira Filho MA, Pimentel IC, Gebrim LH, Simões Mde J, Baracat EC (2005) Quantification of angiogenesis induced in rabbit cornea by breast carcinoma of women treated with tamoxifen. J. Surg. Oncol. 90, 77-80.
31. Ferrara N, Davis-Smyth T (1997) The biology of vascular endothelial growth factor. Endocr. Rev. 18, 4-25.
32. Relf M, LeJeune S, Scott PA, Fox S, Smith K, Leek R, Moghaddam A, Whitehouse R, Bicknell R, Harris AL (1997) Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor β-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis. Cancer Res. 57, 963-969.
33. Zhang HT, Scott PA, Morbidelli L, Peak S, Moore J, Turley H, Harris AL, Ziehe M, Bicknell R (2000) The 121 amino acid isoform of vascular endothelial growth factor is more strongly tumorigenic than other splice variants in vivo. Br. J Cancer 83, 63-68.
34. Hara H, Akisue T, Fujimoto T, Imabori M, Kawamoto T, Kuroda R, Fujioka H, Yamamoto T, Doita M, Kurosaka M (2006) Expression of VEGF and its receptors and angiogenesis in bone and soft tissue tumors. Anticancer Res. 26, 4307-4311.
35. Christodoulakos G, Lambrinoudaki I, Panoulis C, Papadias C, Sarandakou A, Liakakos T, Alexandrou A, Creatsas G (2004) Effect of hormone therapy, tibolone and raloxifene on circulating vascular endothelial growth factor in Greek postmenopausal women. Eur. J Endocrinol. 151, 187-192.
36. Lam PM, Yim SF, Briton-Jones C, Chung TK, Haines C (2004) Raloxifene therapy in postmenopausal women is associated with a significant reduction in the concentration of serum vascular endothelial growth factor. Fértil. Steril. 81, 393-397.
37. Banks RE, Forbes MA, Kinsey SE, Stanley A, Ingham E, Walters C, Selby PJ (1998) Release of the angiogenic cytokine vascular endothelial growth factor (VEGF) from platelets: significance for VEGF measurements and cancer biology. Br. J Cancer 11, 956-964.